drugset / Trial / NCT01252186

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

NCT01252186

Phase 2 Completed 265 enrolled Teva Women's Health
RandomizedParallel-groupOpen-labelBasic science

Summary

This study is being conducted to evaluate the impact of a 91-day extended cycle oral contraceptive compared to two 28-day oral contraceptive regimens on hemostatic parameters in healthy women.

Timeline

Start
2010-11
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Desogestrel Small molecule 150 ug Oral
Comparator Levonorgestrel Small molecule 150 ug Oral
Comparator Marvelon Small molecule 30 ug Oral
Comparator ethinyl estradiol Small molecule 30 ug Oral